Short Interest in Genprex, Inc. (NASDAQ:GNPX) Declines By 5.9%

Genprex, Inc. (NASDAQ:GNPX) was the target of a large decline in short interest in the month of November. As of November 15th, there was short interest totalling 342,100 shares, a decline of 5.9% from the October 31st total of 363,400 shares. Approximately 4.3% of the company’s shares are short sold. Based on an average daily volume of 9,330,000 shares, the short-interest ratio is currently 0.0 days.

Genprex Price Performance

NASDAQ:GNPX opened at $1.09 on Wednesday. Genprex has a fifty-two week low of $0.28 and a fifty-two week high of $14.40. The business has a 50 day moving average price of $1.20 and a 200-day moving average price of $1.43.

Institutional Trading of Genprex

An institutional investor recently raised its position in Genprex stock. Armistice Capital LLC raised its holdings in Genprex, Inc. (NASDAQ:GNPX) by 122.7% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 218,000 shares of the company’s stock after buying an additional 120,132 shares during the quarter. Armistice Capital LLC owned about 10.39% of Genprex worth $411,000 at the end of the most recent quarter. Institutional investors own 14.05% of the company’s stock.

Genprex Company Profile

Genprex, Inc, a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes.